Please join us for a conversation about the HEALEY ALS Platform Trial on Wednesday, April 8 at 3:00 pm.
Daylight saving time: Easing the transition. Daylight saving time: Easing the transition. This year, daylight saving time begins at 2 am on March 8. Here, Elizabeth Klerman, MD, PhD, of the MGH Department of Neurology, discusses possible side effects
In some cases, childhood maltreatment may be a contributing factor to developing functional neurological disorder, yet the links between the two have been poorly understood thus far.
The findings could help in identifying and developing new therapies for people with Gulf War illness as well as other chronic conditions linked to neuroinflammation.
Sean M. Healey & AMG Center for ALS At Mass General Receives “May Proceed” notice for three drugs in first ALS platform trial
BOSTON – The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS).
This symposium is a 2 day educational and networking forum designed for physicians,nurses, advanced practitioners, pharmacists, allied health professionals, researchers,and students with a focus on the emerging science of genetic therapies and theevaluation, management, and treatment of Alzheimer's Disease, ALS, brain tumors and metastases, and stroke.
The ALS Association today announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS). A
Study reveals insights on hidden sexual-arousal disorder. Study reveals insights on hidden sexual-arousal disorder. Key Takeaways • Persistent genital arousal disorder is characterized by spontaneous and unwanted sexual arousal unrelated to desire
Highlights from the meeting included a robust discussion moderated by Dr. Robert Brown with guest speakers Drs. Jean-Pierre Julien, from Laval Universities Department of Psychiatry and Neuroscience, Saud Sadiq, Director and Chief Research Scientist from Tisch MS Research Center of New York and Laura Paulsen, from EnClear Therapies, who spoke on the role of CSF toxicity in ALS pathophysiology.
Inaugural Mass General Hospital HEALEY Center International Prize for Innovation in ALS Awarded at 2019 MND Meeting in Perth, Australia
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS. Team members include researchers from academia and industry.
The Patient Gateway provides secure online access to your health information whenever you need it. Check upcoming appointments, communicate with your doctor’s office, review medications and pay medical bills—all seamlessly online 24/7.